Generic selectors
Exact matches only
Search in title
Search in content
Filter by Categories
15th National Conference of the IAOMFP, Chennai, 2006
Abstract
Abstracts from current literature
Acne in India: Guidelines for management - IAA Consensus Document
Addendum
Announcement
Art & Psychiatry
Article
Articles
Association Activities
Association Notes
Award Article
Book Review
Brief Report
Case Analysis
Case Letter
Case Letters
Case Notes
Case Report
Case Reports
Clinical and Laboratory Investigations
Clinical Article
Clinical Studies
Clinical Study
Commentary
Conference Oration
Conference Summary
Continuing Medical Education
Correspondence
Corrigendum
Cosmetic Dermatology
Cosmetology
Current Best Evidence
Current View
Derma Quest
Dermato Surgery
Dermatopathology
Dermatosurgery Specials
Dispensing Pearl
Do you know?
Drug Dialogues
e-IJDVL
Editor Speaks
Editorial
Editorial Remarks
Editorial Report
Editorial Report - 2007
Editorial report for 2004-2005
Errata
Erratum
Focus
Fourth All India Conference Programme
From Our Book Shelf
From the Desk of Chief Editor
General
Get Set for Net
Get set for the net
Guest Article
Guest Editorial
History
How I Manage?
IADVL Announcement
IADVL Announcements
IJDVL Awards
IJDVL AWARDS 2015
IJDVL Awards 2018
IJDVL Awards 2019
IJDVL Awards 2020
IJDVL International Awards 2018
Images in Clinical Practice
In Memorium
Inaugural Address
Index
Knowledge From World Contemporaries
Leprosy Section
Letter in Response to Previous Publication
Letter to Editor
Letter to the Editor
Letter to the Editor - Case Letter
Letter to the Editor - Letter in Response to Published Article
LETTER TO THE EDITOR - LETTERS IN RESPONSE TO PUBLISHED ARTICLES
Letter to the Editor - Observation Letter
Letter to the Editor - Study Letter
Letter to the Editor - Therapy Letter
Letter to the Editor: Articles in Response to Previously Published Articles
Letters in Response to Previous Publication
Letters to the Editor
Letters to the Editor - Letter in Response to Previously Published Articles
Letters to the Editor: Case Letters
Letters to the Editor: Letters in Response to Previously Published Articles
Medicolegal Window
Messages
Miscellaneous Letter
Musings
Net Case
Net case report
Net Image
Net Letter
Net Quiz
Net Study
New Preparations
News
News & Views
Obituary
Observation Letter
Observation Letters
Oration
Original Article
ORIGINAL CONTRIBUTION
Original Contributions
Pattern of Skin Diseases
Pearls
Pediatric Dermatology
Pediatric Rounds
Perspective
Presedential Address
Presidential Address
Presidents Remarks
Quiz
Recommendations
Regret
Report
Report of chief editor
Report of Hon : Treasurer IADVL
Report of Hon. General Secretary IADVL
Research Methdology
Research Methodology
Resident page
Resident's Page
Resident’s Page
Residents' Corner
Residents' Corner
Residents' Page
Retraction
Review
Review Article
Review Articles
Revision Corner
Self Assessment Programme
SEMINAR
Seminar: Chronic Arsenicosis in India
Seminar: HIV Infection
Short Communication
Short Communications
Short Report
Special Article
Specialty Interface
Studies
Study Letter
Supplement-Photoprotection
Supplement-Psoriasis
Symposium - Contact Dermatitis
Symposium - Lasers
Symposium - Pediatric Dermatoses
Symposium - Psoriasis
Symposium - Vesicobullous Disorders
SYMPOSIUM - VITILIGO
Symposium Aesthetic Surgery
Symposium Dermatopathology
Symposium-Hair Disorders
Symposium-Nails Part I
Symposium-Nails-Part II
Systematic Reviews and Meta-analysis
Tables
Technology
Therapeutic Guidelines
Therapeutic Guidelines - IADVL
Therapeutics
Therapy
Therapy Letter
View Point
Viewpoint
What’s new in Dermatology

Translate this page into:
[gtranslate]

Research Methdology
2003:69:4;300-302
PMID: 17642920

Ethics Committee

G Tyebkhan
 Sun Pharmaceuticals Industries Ltd., Mumbai, India

Correspondence Address:
G Tyebkhan
B-6/7, Nazir Apartments, Azad Road, Vile Parle (East), Mumbai - 400057
India
How to cite this article:
Tyebkhan G. Ethics Committee . Indian J Dermatol Venereol Leprol 2003;69:300-302
Copyright: (C)2003 Indian Journal of Dermatology, Venereology, and Leprology
Introduction

Research in biomedical sciences has produced substantial social benefits but has also posed troubling ethical issues. The need to regulate such research culminated in the drafting of the Declaration of Helsinki, the ethical guiding document for human experimentation.

The Declaration of Helsinki and its further revisions, however, cannot in isolation improve the ethics of research. That requires ′people′ to apply international codes to local circumstances and ensure implementation of research ethics processes.[1] One such mechanism, as prescribed in the Declaration, is the ′independent ethics committee′ (IEC)FNx01 or the ′institutional review board′, referred to by the acronym IRB.

Why ethics committees?

The function of the IEC / IRB is to oversee and monitor any clinical research project, thereby ensuring adherence to scientific, ethical and legal guidelines.[2] In both these functions the IRB is charged with assessing the scientific merit of research studies and assuring respectful treatment and safety of research participants.[3] Thus, ethics committees are required to meet the mandate of the declaration of Helsinki, to protect study subjects (their well being, rights and confidentiality) and to make clinical research socially respectable and acceptable to regulatory authorities and journal editors.

Composition of an ethics committee

An IEC / IRB comprises both professionals and community representatives. It must have a minimum of 5 members of varying backgrounds; at least one member must be from a non-scientific area and at least one must be unaffiliated with the institution sponsoring the IRB.[4] The committee should include at least one member with a thorough knowledge of the scientific aspects of clinical research and of methods of research synthesis.[5] A legal expert, social scientist, theologian and a women′s representative, would be the desired composition. The recommended number of members is twelve to fifteen.[6]

As per the Declaration of Helsinki, the ethical review committee must be independent of the investigator, the sponsor, or any other kind of undue influence. While the chairperson is preferably from outside the institution, the member-secretary may belong to the same institution that would conduct the business of the committee. The committee should be in conformity with the laws and regulations of the country in which the research experiment is being performed.[7]

Committees have the power to co-opt members, especially when dealing with new technologies such as genetic research. The value of such a temporarily co-opted specialist member is immense.[5] Independence and competence are the two hallmarks of an ethics committee.[6]

Role of the ethics committee in clinical research

Ethics committees are charged with overseeing all aspects of human research.[8] Their main role is to assess both the scientific and ethical aspects of submitted protocols. The research protocol must be reviewed and approved by a local IRB before commencing a clinical trial. The committee should be satisfied that investigators who take on research commitments, can conduct these studies adequately. It is empowered to exempt, approve, disapprove or require modifications in the submitted protocol of proposed studies. Its subsequent responsibilities include evaluating the annual progress report, approving amendments and taking stock of any adverse events.[5],[9],[10] Thus, a clinical trial is subject to continuing IEC / IRB review until closure.[11]

Broadly speaking, ethics committees have a wider responsibility to promote public interest by helping to ensure that relevant research is done, that research efforts are not being duplicated, and that patients are not being denied the benefits of already established effective therapies.[12]

Functioning of an ethics committee

Each ethics committee should have its own standard operating procedure. The ethical review should be done through formal meetings with a proper quorum. Efforts should be made to reach a unanimous decision; if not, the proposal could be voted upon, voting rights being allowed to attending, permanent members only. The protocol amendments also need to be approved either by the full committee, if important, or by the Chairman′s action, if minor (expedited approval).[13]

Procedure to obtain approval

Most ethics committees have a format designed for submission of a protocol for review. The investigator is responsible for obtaining approval and for providing the necessary documents before commencing a clinical trial. The main documents that need to be submitted include:

l Protocol and case record form (CRF)

l Informed consent form (in a language understood by patients)

l Subject recruitment procedure (and documents such as a patient information leaflet in a language understood by patients) related to it

l Investigator brochure (a collection of data consisting of all clinical as well as non-clinical information available on the investigational product prior to the onset of clinical trial)

l Curriculum vitae of all investigators and the facilities at their disposal

l Details of the research grant and compensation available to the subjects

l Plans for publication of results, whether positive of negative

l Regulatory clearances (e.g. from the Drug Controller of India)

Most ethics committees charge a nominal fee for providing their services.

Scope or domain of the ethics committees

To assess the merit of a project, the IECs / IRBs must ask some basic questions:

l Does the project ask an important question?

l Will the study design allow that question to be answered?

l Are the risks to the research subjects acceptable?

l Will the autonomy of the subjects be respected by their informed consent being obtained?

Financial questions, such as "Can the trust afford this study?" should not be a problem for the ethics committee.[14]

Publication and ethics committee

The accountability of IECs / IRBs would improve if they ensure that the results of the trials that they approve are publicly available within a reasonable period of time after completion of data collection.[12] Rarely do ethics committees demand as a condition of approval, that any research project be submitted for publication. Certain IRBs in Australia have, however, adopted this requirement for all projects involving human or animal subjects.[15]

Future considerations

Recently, there was a recommendation for creating a human research participant protection program. This would in effect replace the existing IECs / IRBs. This recommendation stems out of the fact that the present system of research review is overloaded and not free from bias. In place of IRBs, three reviewing bodies, one for scientific studies, one for potential conflicts of interest and a third for ethical reviews would exist. A consolidated final decision would be made based on all the three reports.[16]

Current scenario

Even today, examples of unethical research are reported regularly, with researchers dazzled by the potential scientific rewards, forgetting the moral and humane principles to which they should adhere. Although the ethical review process in many, particularly developing, countries is weak or inadequate, it does not justify any omission.[17] Ethics committees thus continue to be a vital safeguard for human experimentation.[14]

Acknowledgements

I would like to sincerely thank Dr. Arun Nanivadekar for his valuable comments

References
1.
Singer PA. Beyond Helsinki: A vision for global health ethics. BMJ 2001;322:747-8.
[Google Scholar]
2.
Roberts L. Ethics and mental illness research. Psychiatric Clin N Am 2002;25:525-45.
[Google Scholar]
3.
Levine RJ. Ethics and regulation of clinical research. Baltimore (MD): Urban and Schwartzenberg; 1986.
[Google Scholar]
4.
Kapp M. Regulating hematology/oncology research involving human participants. Hematology/Oncology Clin 2002;16:1449-61.
[Google Scholar]
5.
Blunt J. Meeting the challenges facing research ethic committees: Some practical suggestions. BMJ 1998;316:58-61.
[Google Scholar]
6.
CDSCO. Good clinical practice: Guidelines for clinical trials on pharmaceutical products. New Delhi: Ministry of Health and Family Welfare; 2001.
[Google Scholar]
7.
Declaration of Helsinki. Section B Clause 13.
[Google Scholar]
8.
Lindenauer P. The role of the IRB in quality improvement: A survey of quality officers, IRB chairs and journal editors. Am J Med 2002;113:575-9.
[Google Scholar]
9.
Pich J. Role of a research ethics committee in follow up and publication of results. Lancet 2003;361:1015-6.
[Google Scholar]
10.
Wichman A. Protecting vulnerable research subjects: Practical realities of IRB review and approval. J Health Care Law Policy 1998;1:88-104.
[Google Scholar]
11.
Peckman S. Local institutional review boards, ethical policy and issues in research involving human participants, Vol. II. Commissioned papers and staff analysis. Betheseda (Md): National Bioethics Advisory Commission; 2001. p. k-1-k-35.
[Google Scholar]
12.
Savulescu J. Are ethics committees behaving unethically? Some suggestions for improving performance and accountability. BMJ 1996;313:1390-3.
[Google Scholar]
13.
Smith T. Review by a local medical REC of the conduct of approved research projects, by examination of patient's case notes, consent forms and research records and by interview. BMJ 1997;314:1588-90.
[Google Scholar]
14.
Alberti K. Local research EC. BMJ 1995;311:639-40.
[Google Scholar]
15.
Pearn J. Publication: An ethical imperative. BMJ 1995;310:1313-5.
[Google Scholar]
16.
Marwick C. Report demands better protection for people in research trials. BMJ 2002;325:796.
[Google Scholar]
17.
Tollman. What are the effects of the 5th revision of the Declaration of Helsinki? BMJ 2001;323:1417-23.
[Google Scholar]
Show Sections